Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
Axon 5051 - Cell signaling and Oncology Library.xls | |
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1254 | Zebularine | DNA methyltransferase inhibitor | €95.00 | |
2469 | YK 4-279 | Inhibitor of ETV1, ERG and interactions of EWS-FLI1 and RNA helicase A | €95.00 | |
2268 | XL 413 hydrochloride | Potent, selective and orally bioavailable CDC7 inhibitor | €120.00 | |
1527 | XAV939 | Tankyrase (TNKS) inhibitor | €80.00 | |
4271 | VVD-214 | Potent, selective, allosteric inhibitor of WRN helicase | Recently added | Inquire |
3801 | Voruciclib | Inhibitor of CDK9 | Inquire | |
2888 | Veliparib dihydrochloride | PARP inhibitor | €90.00 | |
1593 | Veliparib | PARP inhibitor | €40.00 | |
2369 | UPF 1069 | PARP-2 inhibitor with >26 fold selectivity over PARP1 | €75.00 | |
2100 | Trovafloxacin mesylate | Inhibitor of bacterial DNA gyrase and Topo IV | €110.00 | |
2914 | TAS-103 dihydrochloride | Dual inhibitor of topoisomerase I (Topo 1) and topoisomerase II (Topo 2) | €95.00 | |
2502 | Talazoparib | Potent, selective, and orally available PARP1/2 inhibitor | €90.00 | |
3605 | TAK-931 | CDC7 inhibitor | €160.00 | |
3587 | STM2457 | First-in-class, highly potent and selective catalytic METTL3 inhibitor | €130.00 | |
4050 | STL427944 | Selective FOXM1 inhibitor | €130.00 | |
1670 | STF 083010 | IRE1α inhibitor | €95.00 | |
2314 | Stattic | Nonpeptidic small-molecule inhibitor of STAT3 activation, dimerization, and nuclear translocation | €50.00 | |
2731 | STAT5 Inhibitor 1 [285986-31-4] | Nonpeptidic small-molecule inhibitor of STAT5 activation | €90.00 | |
2200 | SRPIN 340 | Selective ATP-competitive inhibitor of SRPK kinase activity | €95.00 | |
2714 | SPHINX31 | Potent and selective inhibitor of SRPK1 kinase activity | €125.00 | |
2764 | SIS3 | Potent and selective inhibitor of Smad3 and TGF-βR1 signaling | €135.00 | |
2347 | SGI 1027 dihydrochloride | Inhibitor of DNMT activity in colon cancer cell lines | €110.00 | |
2531 | SCR7 pyrazine | DNA ligase IV mediated inhibitor of NHEJ | €65.00 | |
3828 | SCH900776 dihydrochloride | Potent, selective and orally bioavailable inhibitor of CHK1 | Inquire | |
2313 | S3I 201 | Potent, cellular STAT3 inhibitor | €90.00 | |
3113 | Rucaparib camsylate | PARP1 inhibitor | €90.00 | |
4003 | RP-6685 | Potent, selective, and orally bioavailable Polθ inhibitor | €160.00 | |
3573 | Ribavirin | Antiviral agent; Suppressor of eIF4E activity | €60.00 | |
1885 | RI-1 | Inhibitor of the central recombination protein RAD51 | €95.00 | |
1691 | RG 108 | DNA methyltransferase inhibitor | €80.00 |